- Home
- FRHC vs ROIV Comparison
FRHC vs ROIV Comparison
Compare FRHC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRHC | ROIV |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FRHC | ROIV |
|---|---|---|
| Price | $133.41 | $21.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $24.31 |
| AVG Volume (30 Days) | 85.3K | ★ 8.2M |
| Earning Date | 02-06-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,563,510,000.00 | $20,329,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $741.42 |
| P/E Ratio | $1,691.67 | ★ N/A |
| Revenue Growth | ★ 16.04 | N/A |
| 52 Week Low | $111.85 | $8.73 |
| 52 Week High | $194.01 | $23.47 |
Technical Indicators
Market Signals| Indicator | FRHC | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 51.68 |
| Support Level | $120.22 | $20.78 |
| Resistance Level | $137.10 | $22.21 |
| Average True Range (ATR) | 4.91 | 0.69 |
| MACD | 0.29 | -0.17 |
| Stochastic Oscillator | 78.14 | 30.46 |
Price Performance
Historical ComparisonAbout FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.